Physician profile
Christopher Eric Shih
NPI 1881699445
$5,609.50
in general payments reported to CMS, 2019-2025
27 companies · $1,229 in 2025
The $1,229 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $294 · 2021: $361 · 2022: $1,002 · 2023: $1,160 · 2024: $1,001 · 2025: $1,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,376 · Education: $14.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,375.60 |
| Education | $14.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,870.05 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Ardelyx, INC. | $438.88 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $422.21 | 2019-2025 | Entyvio, Gattex |
| Pfizer INC. | $420.51 | 2019-2025 | |
| Celgene Corporation | $400.09 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $326.66 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $264.11 | 2019-2025 | Xifaxan, Plenvu |
| Genzyme Corporation | $254.23 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $246.45 | 2022-2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $122.09 | 2024 | Terlivaz |
| E.R. Squibb & Sons, L.L.C. | $120.72 | 2022 | |
| Intercept Pharmaceuticals, INC. | $115.67 | 2019-2023 | Ocaliva |
| Gilead Sciences, INC. | $93.53 | 2022-2025 | |
| Lilly USA, LLC | $92.06 | 2024-2025 | Omvoh |
| Amgen INC. | $59.67 | 2020-2023 | Amjevita |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $53.64 | 2020-2022 | |
| Madrigal Pharmaceuticals | $52.09 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $51.46 | 2023 | Sucraid |
| Shionogi INC | $46.41 | 2019 | |
| Phathom Pharmaceuticals, INC. | $40.01 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $39.60 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $29.58 | 2025 | Rebyota |
| Alnylam Pharmaceuticals INC. | $21.96 | 2023 | Onpattro |
| Celltrion USA INC. | $14.08 | 2023 | Yuflyma |
| Fresenius Kabi USA, LLC | $13.74 | 2025 | Idacio |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Shih listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.